Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ependymoma × Thalidomide × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 48 Neoplasms, Plasma Cell 19 Central Nervous System Neoplasms 10 Prostatic Neoplasms 9 Glioblastoma 9 Recurrence 8 Brain Neoplasms 8 Neoplasms 7 Melanoma 7 Gliosarcoma 7 Carcinoma, Non-Small-Cell Lung 6 Waldenstrom Macroglobulinemia 5 Sarcoma 5 Leukemia 5 Glioma 5 Colorectal Neoplasms 5 Myeloproliferative Disorders 4 Lymphoma 4 Lung Neoplasms 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Kidney Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Hepatocellular 4 Myelodysplastic-Myeloproliferative Diseases 3 Myelodysplastic Syndromes 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3 Immunoglobulin Light-chain Amyloidosis 3 Colonic Neoplasms 3 Astrocytoma 3

Interventions

Magnetic Resonance Spectroscopy 9 Bevacizumab 9 Temozolomide 8 Cyclophosphamide 8 Etoposide 7 X-Rays 6 Phantoms, Imaging 6 Specimen Handling 5 Nuclear Medicine Department, Hospital 5 Irinotecan 4 Filgrastim 4 Cisplatin 4 Carboplatin 4 Biopsy 4 Radiotherapy 3 Erlotinib Hydrochloride 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 sargramostim 2 palbociclib 2 olaparib 2 larotrectinib 2 ivosidenib 2 etoposide phosphate 2 erdafitinib 2 ensartinib 2 Vincristine 2 Vemurafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡